F-star Therapeutics, Inc. Common Stock
FSTX
FSTX was delisted on the 8th of March, 2023.
40 hedge funds and large institutions have $29M invested in F-star Therapeutics, Inc. Common Stock in 2022 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 9 increasing their positions, 11 reducing their positions, and 10 closing their positions.
500% more call options, than puts
Call options by funds: $72K | Put options by funds: $12K
7% less funds holding
Funds holding: 43 → 40 (-3)
18% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 11
30% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 10
45% less capital invested
Capital invested by funds: $53.2M → $29M (-$24.2M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Russell Investments Group
London,
United Kingdom
|
+$1.32M |
| 2 |
Barclays
London,
United Kingdom
|
+$278K |
| 3 |
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
|
+$203K |
| 4 |
Millennium Management
New York
|
+$150K |
| 5 |
Goldman Sachs
New York
|
+$125K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
-$2.63M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$551K |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$485K |
| 4 |
AFM
Anson Funds Management
Dallas,
Texas
|
-$460K |
| 5 |
Truist Financial
Charlotte,
North Carolina
|
-$397K |
FSTX Hedge Fund Activity: Q1 2022 in Review
40 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in F-star Therapeutics, Inc. Common Stock (FSTX) for Q1 2022, worth a combined $29M — down 45% from $53.2M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of FSTX and 7 opened new positions — a net loss of 3 holders — while 11 trimmed existing stakes and 9 added.
The largest buyer was Russell Investments Group, adding an estimated $1.32M. The largest seller was Janus Henderson Group, exiting entirely with an estimated $2.63M sold.
- 40 institutional investors held F-star Therapeutics, Inc. Common Stock (FSTX) as of Q1 2022, down from 43 in Q4 2021.
- Funds reported $29M of F-star Therapeutics, Inc. Common Stock stock for Q1 2022, down 45% quarter-over-quarter.
- 7 funds opened new F-star Therapeutics, Inc. Common Stock positions in Q1 2022 and 10 closed out, a net change of -3 holders.
- The largest F-star Therapeutics, Inc. Common Stock buyer in Q1 2022 was Russell Investments Group, an estimated $1.32M added.
- The largest F-star Therapeutics, Inc. Common Stock seller in Q1 2022 was Janus Henderson Group, an estimated $2.63M sold.
Based on aggregated 13F filings for Q1 2022.